Pliant Therapeutics (NASDAQ:PLRX) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has a $36.00 target price on the stock. A number of other equities analysts also recently weighed in on the stock. Oppenheimer boosted their price […]

Related Keywords

United States ,Entrypoint ,British Columbia ,Canada , ,Entrypoint Capital ,Vanguard Group Inc ,Pricet Rowe Associates Inc ,Capital International Investors ,Needham Company ,Royal Bank ,Redmile Group ,Pliant Therapeutics Inc ,Citigroup ,Pliant Therapeutics ,Free Report ,Therapeutics Stock Down ,Get Free Report ,International Investors ,Point Capital ,Vanguard Group ,Pliant Therapeutics Daily ,